These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 10945011

  • 1. [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
    Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Ohno R.
    Gan To Kagaku Ryoho; 2000 Jul; 27(8):1160-7. PubMed ID: 10945011
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
    Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R.
    J Clin Oncol; 1996 Jan; 14(1):204-13. PubMed ID: 8558199
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
    Nagura E, Kimura K, Yamada K, Ohta K, Maekawa T, Takaku F, Uchino H, Masaoka T, Amaki I, Kawashima K.
    Cancer Chemother Pharmacol; 1994 Jan; 34(1):23-9. PubMed ID: 8174198
    [Abstract] [Full Text] [Related]

  • 8. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults.
    Ohno R, Yokomaku S, Okumura M, Nagai T, Kitaori K, Ito T, Takeo T, Sugiura I, Yano K, Ito Y.
    Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832
    [Abstract] [Full Text] [Related]

  • 9. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T, Urasaki Y, Yamaguchi M, Ueda M, Morinaga K, Haba T, Sugiyama T, Nakao S, Origasa H, Umehara H, Ueda T.
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm A, Hippe E, Jans H, Jensen KB.
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 15. [Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
    Ishige K, Takagi T, Oguro M.
    Gan To Kagaku Ryoho; 1984 Jul; 11(7):1475-9. PubMed ID: 6588925
    [Abstract] [Full Text] [Related]

  • 16. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
    Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A, German AML Cooperative Group.
    J Clin Oncol; 2003 Dec 15; 21(24):4496-504. PubMed ID: 14673036
    [Abstract] [Full Text] [Related]

  • 17. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
    Park HS, Kim DW, Kim CC, Kim HK, Kim JS, Hwang TJ, Kim HJ, Kim HS, Song HS, Park JW, Ahn HS, Chung TJ, Cho KS, Lee KS, Choi YM.
    Semin Hematol; 1996 Oct 15; 33(4 Suppl 3):24-9. PubMed ID: 8916313
    [Abstract] [Full Text] [Related]

  • 18. [Comparison of conventional chemotherapy and short-term intensive chemotherapy in adult acute myeloid leukemia].
    Ohshima T.
    Rinsho Ketsueki; 1989 Aug 15; 30(8):1175-7. PubMed ID: 2601028
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5).
    Sperr WR, Piribauer M, Wimazal F, Fonatsch C, Thalhammer-Scherrer R, Schwarzinger I, Geissler K, Knöbl P, Jäger U, Lechner K, Valent P.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):3965-71. PubMed ID: 15217926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.